Thus, this target was further validated in patients with schizophrenia and MDD by clinical trials with dual TAAR1 and 5-HT1A receptor agonist Ulotaront (SEP-363856), which demonstrated efficacy and a favorable safety profile [11,12]. This evidence concerns the gene TAAR1 and major depressive disorder.